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ABSTRACT
Babesia microti Cysteine Protease-1 as a Target for Vaccine Development.
(August 2005)
Allison Melissa James, B.S., University of California at Irvine
Chair of Advisory Committee:  Dr. Patricia Holman
Babesia species have a worldwide distribution, affecting a wide range of mammalian
hosts. The major route of transmission is inoculation by an infected Ixodid tick. Babesia
species of major economic concern are those that cause bovine and equine babesiosis.
Historically, bovine Babesia species, Babesia bovis and Babesia bigemina caused
significant economic losses in the United States in the 1860’s, as thousands of cattle
died. Also, outbreaks of equine babesiosis, caused by Babesia equi or Babesia caballi,
have occurred in the United States resulting in the death of some horses and millions of
dollars in losses. A constant risk of reinfection with bovine and equine Babesia species
exists, as stray and smuggled animals from Mexico, where bovine babesiosis is endemic,
may carry infected ticks as they cross the border, and, thousands of horses from B. equi-
and B. caballi-endemic regions are imported through Florida every year.
Vaccines have been developed for a number of Babesia species, none of which result
in sterile immunity. The live attenuated vaccine is the most commonly used vaccine
against Babesia species. However, the basis for the vaccine is to maintain a carrier state
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in order to prevent disease. Other vaccine designs have been developed to invoke
protection without a carrier state but have been unsuccessful.
It has been shown that the cysteine protease is important in the life cycle of a number
of parasitic organisms, making it a good target for vaccine development. The vaccine
design for this study incorporated the cysteine protease of Babesia microti. Babesia
microti naturally infects Peromyscus leucopus (white-footed mouse) and is the major
cause of human babesiosis in the United States. Using B. microti in the vaccine design
allowed for the use of a mouse model to determine whether the cysteine protease of
other economically important Babesia species may make a good vaccine target. The
vaccine design incorporated a prime-boost strategy, priming with DNA encoding the
cysteine protease and boosting two times with either DNA encoding the cysteine
protease or cysteine protease peptide, followed by parasite challenge. Analysis of daily
percent parasitemias, packed cell volume, and seroconversion of all groups revealed that
a protective immune response against B. microti was not elicited by this vaccine
strategy.
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11. INTRODUCTION
Babesia species are taxonomically classified in the phylum Apicomplexa, class
Piroplasmea, and order Piroplasmida (Levine, 1971). The apical complex organelle
(rhoptries, etc.) places the parasite as an Apicomplexan while the pear-shaped
intraerythrocytic form of the parasite characterizes it as a piroplasm. Babesia species are
divided into two groups based on merozoite size. The small Babesia are1-2.5 mm and
include Babesia gibsoni, Babesia microti, and Babesia divergens. The large Babesia
species are 2.5- 5.0 mm and include Babesia bigemina, Babesia caballi, and Babesia
canis. Based on 18s ribosomal RNA gene sequences, the large and small Babesia species
do not fall into two corresponding phylogenetic groups (Persing et al., 1995).
Babesia is capable of parasitizing many mammalian species, including canine,
bovine, equine, and human. Babesia species that cause bovine babesiosis and equine
piroplasmosis are of economic importance, supporting the need for chemotherapeutic
agents in addition to vaccines. Babesia equi and B. caballi have a worldwide distribution
and are the cause of equine piroplasmosis. Bovine babesiosis, also with worldwide
distribution, can be caused by B. bigemina, Babesia major, Babesia bovis, or
B. divergens (Levine, 1985).
Both B. equi and B. caballi can be transmitted by Boophilus, Hyalomma,
Dermacentor, and Rhipicephalus species of tick (Levine, 1985; Friedhoff, 1988). Equine
____________
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2piroplasmosis is characterized by anemia, icterus and fever and, if the horse does not die,
a carrier state will be established. The carrier state is of specific importance to race
horses because the parasites cause a reduction in the oxygen-carrying capacity of the
blood (Hailat et al., 1997; Olivier et al., 1997). Babesia equi and B. caballi infections
also have the potential to keep horses from being imported and exported, which is of
major importance to equestrian events such as those that take place at the Olympics
(Friedhoff et al., 1990). In the United States, the infection state is determined
serologically by the complement fixation test. However, this method of detection may
not detect new or acute infections because the equine host may not have had time to
mount an immune response. It is critical to produce a vaccine against equine babesiosis
that will prevent other equine hosts from being infected. If the equine host becomes
infected, treatment depends on the species of Babesia. Babesia caballi can be cleared
with imidocarb, however there is not an effective treatment to clear B. equi infections
and the dosage of imidocarb that would be required for B. equi is close to the LD50
(Adams, 1981; Kuttler, 1981; Kuttler et al., 1987).
Bovine babesiosis can be caused by a number of Babesia species, including
B. bigemina, B. bovis, B. divergens, and B. major (Levine, 1985; Mehlhorn and Kakoma,
1994). For historical and pathogenic reasons, the most economically important causes of
bovine babesiosis are B. bigemina, B. bovis, and B. divergens (Smith and Kilborne,
1893; Dolman, 1969; Levine, 1985; Mehlhorn and Kakoma, 1994; Bowers, 2000).
Babesia bigemina and B. bovis are said to have been the cause of death of over 15,000
head of cattle in the 1860’s after seemingly healthy cattle were transported to Illinois and
3Indiana from Texas. During this time, mortality rates approached 90% (Smith and
Kilborne, 1893). It was later estimated by the United States Congress that the economic
loss associated with the babesiosis outbreak was approximately $130.5 million
(equivalent to billions of dollars today) (Dolman, 1969; Bowers, 2000). Besides loss of
cattle head, the industry suffered from the severe weight loss and decreased milk
production associated with the disease. The cattle fever tick eradication program was put
into action years later, clearing the vector ticks for bovine babesiosis, Boophilus
annulatus and Boophilus microplus, from the United States (Bowers, 2000; Marquart,
2000; Burkot and Graves, 2000). However, the tick is endemic in Mexico causing loss of
livestock and propagating the number of infected ticks. Texas is still at risk of becoming
reinfected as stray and smuggled animals from Mexico cross the border (Bowers, 2000).
In fact, 50% of the cattle and 20% of the equids that have been seized during smuggling
attempts into the United States were infested with cattle fever ticks (Bowers, 2000).
Babesia bovis, B. bigemina, and B. divergens are the most economically important
causes of bovine babesiosis. Babesia bigemina is geographically limited to the tropics
and subtropics of Africa, Australia, Europe, the Middle East, Central and South
America, and Mexico by the geographic distribution of Boophilus ticks (Levine, 1985;
Mehlhorn and Kakoma, 1994). Babesia bovis has the same geographic distribution as
B. bigemina and is vectored by Boophilus spp. ticks, however, it is also distributed
throughout some European countries, where it is vectored by Ixodes ricinus (Burkot and
Graves, 2000). Babesia divergens is limited in geographic distribution to northern
Europe and the United Kingdom by the range of the tick vector, I. ricinus (Burkot and
4Graves, 2000). In addition to being a cause of bovine babesiosis, B. divergens is the
primary cause of human babesiosis in Europe (discussed below). Babesia bigemina,
B. bovis, and B. divergens are usually highly pathogenic in bovine adults but not in
calves and B. bovis is generally more pathogenic than B. bigemina and B. divergens
(Levine, 1985; Mehlhorn and Kakoma, 1994). The pathogenesis caused by B. bigemina,
B. bovis, and B. divergens is similar except bovine hosts infected with B. bovis may
incur lesions of the cerebrum and cerebellum, where capillaries are swollen with infected
erythrocytes (Mehlhorn and Kakoma, 1994). Generally, acute cases of bovine babesiosis
will be associated with a high temperature (106-108ºF), lethargy, and hemoglobinuria,
and might result in death if the bovine host is not treated (Levine, 1985). Chronic cases
of bovine babesiosis generally do not present a high temperature or hemoglobinuria but
are lethargic and unwilling to eat, resulting in reduced milk production and poor weight
gain (Gray and Harte, 1985; Levine, 1985; Gorenflot et al., 1998). Cattle that survive
will be premunized by a latent infection, which will last for the life of the bovine host if
it is infected by B. bigemina. If the bovine host is infected by B. bovis or B. divergens,
premunization will last no more than two years without a boost in immunity by re-
infection (Levine, 1985).
Babesia bovis, B. bigemina, and B. divergens can be treated with imidocarb, but the
goal of treatment is to reduce parasitemia and pathogenesis, leaving the bovine host to
develop a carrier state (Mehlhorn and Kakoma, 1994). Vaccines have been designed to
incorporate the fact that young cattle in endemic regions display a level of protection
against infection with the Babesia species of that region. It is uncertain what factor(s)
5influence the protection seen in calves. A relationship has been shown between age-
related immunity and the release of Th1 cytokines (IL12, IFNg) in addition to natural
killer cells and nitric oxide synthase mRNA expression in the spleen (Goff et al., 2001;
Goff et al., 2002; Goff et al., 2003). When the calves are infected, they are usually
protected from developing signs of disease. The calves become carriers after exposure,
premunized against future infection. Cattle older than 6 months of age are not protected
(Christensson, 1989). Vaccines that premunize young cattle by inoculation with live
Babesia parasites protect against natural infection by mounting a strong and rapid
immune response to prevent disease (Mahoney, 1977). However, problems associated
with this vaccine design will be discussed below.
Other important species of Babesia include Babesia canis and B. gibsoni, which are
the primary species that infect domestic dogs and wild canids. Babesia canis and
B. gibsoni are found worldwide and can be transmitted by Rhipicephalus sanguineus or
Dermacentor reticulatus ticks (Levine, 1985). Babesia canis pathogenesis may involve
the circulatory and respiratory systems, eyes, and central nervous system. When the
central nervous system is involved, the signs might be confused with rabies (Levine,
1985). Dogs that are recovering from B. canis will continue to suffer from erythrocyte
loss despite declining parasitemias, which does not occur among other Babesia species.
Babesia gibsoni is highly pathogenic in dogs, causing marked anemia, fever,
hepatosplenomegaly, constipation, and, contrary to B. canis, hemoglobinuria. Another
difference between B. gibsoni and B. canis is that the pathogenicity of the latter varies
depending on subspecies (Levine, 1985; Zahler et al., 1998). Importation of dogs into
6B. gibsoni-endemic regions carries serious risk, with infected dogs dying within four
weeks (Levine, 1985). Treatments are not as effective against B. gibsoni as they are
against B. canis, however, dogs that have recovered from pathogenesis caused by
B. canis or B. gibsoni will remain in a state of premunition in endemic areas. In the
absence of re-infection, protection only lasts up to a year (Levine, 1985).
The first documented case of human babesiosis occurred in Europe in a Yugoslavian
man in 1957 (Skrabalo and Deanovic, 1957). Since then, more than 30 cases have been
reported in Europe and a number of cases have been reported in China, Egypt, Mexico,
South Africa, and Taiwan. Hundreds of cases have been reported in the United States
(Osorno et al., 1976; Li and Meng, 1984; Michael et al., 1987; Bush et al., 1990; Shih et
al., 1997). The clinical presentation of human babesiosis can range from a silent
infection to a fulminating disease that is comparable to malaria, resulting in severe
hemolysis. Splenectomized and other immune-suppressed individuals have more severe
clinical signs, sometimes resulting in death. Human babesiosis in Europe is most
commonly caused by B. divergens, with cases coinciding with the seasonal activity of
I. ricinis and close proximity to cattle ranches, whereas the primary cause of human
babesiosis in North America is B. microti, which is vectored by Ixodes scapularis (syn.
Ixodes dammini (Oliver et al., 1993)). There have been a few cases of human babesiosis
caused by B. microti in Europe, but the tick vector, Ixodes trianguliceps, does not feed
on humans under normal circumstances so transmission is therefore unlikely (Telford et
al., 1993; Gorenflot et al., 1998). There have also been a small number of human
babesiosis cases caused by Babesia organisms referred to as WA1, CA1, and MO1,
7which have slight phylogenetic differences from other characterized Babesia species
(Quick et al., 1993; Thomford et al., 1994; Persing et al., 1995; Herwaldt et al., 1996).
In the United States, more than 300 cases of human babesiosis have been diagnosed
since 1969 and within the last decade the frequency of diagnosed cases has increased
(Kjemtrup and Conrad, 2000). The rise in the number of diagnosed cases might be
attributed to a number of factors, which may include increased awareness in the medical
community, more individuals participating in outdoor activities, and urban overlap with
environments endemic for the reservoir host, Peromyscus leucopus (white footed
mouse), and the vector tick, I. scapularis (Healy et al., 1976; Etkind et al., 1980;
Spielman et al., 1981; Piesman et al., 1987; Gorenflot et al., 1998; Kjemtrup and Conrad,
2000). One reason for increased awareness among medical professionals is the fact that
B. microti can be co-transmitted with Borrelia burgdorferi, the causative agent of Lyme
disease, by I. scapularis (Hofmeister et al., 1998).
Babesia microti, which produces flu-like symptoms in addition to hemolytic anemia,
can be life threatening in immune-compromised patients. Individuals who are not
immune compromised may still experience persistent parasitemia and fatigue, despite
treatment. There is also concern associated with transmission of the parasite through
blood transfusion or transplacental transmission, in addition to organ transplant acquired
cases (Jacoby et al., 1980; Grabowski et al., 1982; Marcus et al., 1982; Smith et al.,
1986; Esernio-Jenssen et al., 1987; Mintz et al., 1991; Slovut et al., 1996; New et al.,
1997; Dobroszycki et al., 1999; Lux et al., 2000).
81.1. Ixodes life cycle
Babesia microti is transmitted through the saliva of the blacklegged deer tick,
I. scapularis, which has three stages of development: larvae, nymph, and adult. Each
stage requires a blood meal to undergo the morphological changes into the next stage.
The adult tick will feed during the fall and spring on the white tailed deer, Odocoileus
virginianus, which does not carry B. microti infection. In the spring, they will lay eggs,
which will hatch into larvae in the summer. The larvae feed preferentially on the white-
footed mouse, P. leucopus, and to a lesser extent, the meadow vole, Microtus
pennsylvanicus, during August and September (Healy et al., 1976). During this stage, the
tick can pick up the parasite from an infected rodent. In 1980 Etkind et al. found
B. microti endemic in the New England white-footed mouse, with infection rates of 40-
60% (Etkind et al., 1980; Spielman et al., 1981). Ixodes scapularis larvae over-winter,
molt to the nymph stage, and then feed indiscriminately from May to July. During the
nymph stage, the Ixodid tick either has another opportunity to pick up the parasite when
feeding on a rodent, or, a nymph previously infected at the larval stage can transmit the
parasite to a rodent or human (Piesman et al., 1986). The nymph will then molt to the
adult stage in the fall and feed preferentially on the white tailed deer. Eggs are laid in the
spring, thus completing the two-year life cycle.
1.2. Life cycle of Babesia species in Ixodid ticks
The life cycles of all species of Babesia are relatively similar except that B. gibsoni,
B. equi, and B. microti do not undergo transovarial transmission through the vector tick
9and the latter two have a pre-erythrocytic schizont stage in lymphocytes (Moltman et al.,
1983; Mehlhorn et al., 1986). It is presumed that Babesia gibsoni also infect
lymphocytes during the schizont stage. Babesia equi, B. microti, and B. gibsoni also
undergo simultaneous division resulting in tetrad formations of the merozoites, whereas
Babesia sensu stricto divide into paired merozoites.
The Ixodid tick will pick up erythrocytes infected with Babesia during a blood meal.
In the tick gut, some of the intraerythrocytic parasites will develop into gametes, which
will fuse and become a zygote (Telford et al., 1993). The zygote then becomes a motile
kinete that migrates through the gut and hemolymph to penetrate a variety of organs,
including fat body cells, nephrocytes, ovary and salivary glands. Babesia sensu stricto
species will undergo transovarial, and sometimes, transstadial transmission, whereas
Babesia sensu lato species (B. equi, B. microti, and B. gibsoni) only undergo transstadial
tick transmission (Mehlhorn and Schein, 1984; Sonenshine, 1991). Transovarial
transmission is the process of the kinetes undergoing asexual reproduction in the ovary
of the adult female tick, infecting the developing eggs, and producing infected larvae
after hatching. Transstadial transmission is signaled once the tick larvae or nymph
begins feeding on a vertebrate host. The kinetes migrate to the fat body cells,
nephrocytes, and salivary glands where they undergo asexual reproduction (Mehlhorn
and Schein, 1984; Telford et al., 1993).
Within days of the infected tick attaching to a host, the kinetes migrate to the
salivary glands to produce sporozoites by sporogony (Mahoney and Mirre, 1977;
Mehlhorn and Schein, 1984). The sporozoites are inoculated into the host with the aid of
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anti-inflammatory and immunosuppressive chemical agents in the tick saliva, which
increase the efficiency of transmission (Ribeiro, 1987). The sporozoites then invade
erythrocytes and undergo merogony to produce two to four merozoites (Rudzinska et al.,
1976). The merozoites exit the cell and infect more erythrocytes, where they either
differentiate into trophozoites, which replicate by budding, producing more merozoites.
Alternatively, the merozoites may enlarge and become gametocytes, which will only
differentiate if they make it back to the tick gut (Rudzinska et al., 1976; Rudzinska et al.,
1979; Rudzinska et al., 1981; Mehlhorn and Schein, 1984; Levine, 1985).
1.3. Morphology
In Giemsa-stained blood smears, B. microti parasites appear as small (1-3 mm) round
or oval rings with darkly staining nucleic material to one side of the ring. Small red dots
may also be seen in with nucleic material. The vacuole within the ring stains light blue to
white. As the parasitemia increases the parasites take on a wide-ranged morphology
including larger sized oval rings, multiply infected erythrocytes, pear-shaped (piriform),
and maltese cross (tetrad) forms.
1.4. Immune response and requirements
In the United States, cases of human babesiosis attributed to B. microti range in
severity from asymptomatic to highly pathogenic and fatal. The degree of parasitosis is
directly related to the efficiency of the host immune response (Parham, 2000). Most
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severe cases are observed in individuals with an immune deficiency, such as previous
splenectomy or acquired immune deficiency syndrome (AIDS) (Markell et al., 1999).
Once Babesia species invade the physical barrier of the host, the host’s innate
immunity may mount a futile inflammatory response, in addition to producing
carbohydrate binding proteins (to fight the invading microorganisms) (Parham, 2000).
When Babesia parasites reach the vascular system, the sporozoites circulate freely in the
plasma. At this point, the parasites are open to attack by the humoral immune system.
Immunoglobulin G (IgG) antibodies can bind to the parasites and label them for
elimination by lymphocytes. However, this stage in the parasite cycle is limited. Once
the parasites enter the erythrocytes, the humoral response is ineffective against the now
intracellular parasite. In fact, Echaide et al. (1998) described the expression of a
B. bigemina-originating protein on the surface of erythrocytes that helps bind IgM,
suggesting that IgM binding might play a role in parasite growth and survival. This was
supported by earlier research that showed that IgM suppressed mice were resistant to
B. microti infection (Rosenberg, 1979). At this stage of the infection, the most effective
immune response to inhibit Babesia is CD4+ T helper cells and the subsequent release of
IFN-g (Ikuo et al., 1994; Shimada et al., 1996).
Several studies have emphasized the importance of Th1 cytokines in host defense
mechanisms against infection caused by various microbial pathogens (Mehlhorn and
Schein, 1998). One of the main problems associated with intracellular parasitic
infections is that a host Th2 response is stimulated, rather than Th1, which exacerbates
the parasite infection (Keene et al., 1990). The presence of CD4+ T cells and IFNg, the
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release of which is mediated by a Th1 immune response, greatly influences the ability of
the host to clear parasitemia. In fact, mice are more susceptible to infection with
B. microti when they are depleted of CD4+ helper T cells, and, consequently, IFNg.
Moreover, the ability of mice to fight infection with B. microti and B. rodhaini is
unaffected when they are depleted of CD8+ helper T cells (Igarashi et al., 1994;
Shimada et al., 1996). Natural Killer (NK) cells and macrophages may also play a role in
fighting babesiosis (Aguilar-Delfin et al., 2003). NK cells and macrophages, in addition
to T cells and B cells, make up the cell populations within the spleen, an organ critical to
fighting babesiosis (Mehlhorn and Kakoma, 1994; Aguilar-Delfin et al., 2003).
Ultimately, the immune system of an animal or individual with babesiosis primarily
requires not only a Th1 response, in order to activate a cytotoxic T-cell response, but
also a Th2 response in order to activate some protective immunity against re-infection or
re-establishment of disease.
1.5. Chemotherapy
It is important to note that animals may go into a chronic carrier-state after being
infected by a Babesia sp., acting as a reservoir of parasites for tick vectors to pass on to
other animals (Levine, 1985). When naïve animals are brought into these areas, the
mortality rate can be as high as 90% (Dolman, 1969; Markell et al., 1999). In a study of
humans infected with B. microti by Krause et al., it was found that a silent Babesia
infection could persist for months to years if the individuals are not treated with anti-
Babesia chemotherapeutic agents (Krause et al., 1998). They also found that individuals
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who receive treatment with clindamycin and quinine might still suffer from a persistent
infection, re-establishment of parasitemia, or side effects from the drugs. An alternative
is the combination of atovaquone and azithromycin, also associated with adverse side
effects but not as commonly. Chemotherapeutic agents do not protect against future
infection and the parasite may go dormant. Consequently, an animal under stress may
experience recrudescence of parasitemia. This highlights the importance of developing a
vaccine that elicits long-term protection. For now, chemotherapeutic agents should still
be used because they are usually effective in lowering parasitemia and the clinical signs
of babesiosis, with the exception of individuals who are immune suppressed (Jacoby et
al., 1980; Smith et al., 1986; Krause et al., 1998).
1.6. Vaccine designs
The frequency of human infections with B. microti is not high enough to invest in
large-scale vaccine production. On the other hand, working with B. microti allows the
use of mice rather than large mammals for vaccine trials all the while gaining knowledge
for vaccine designs that may work for more economically important Babesia species.
Various Babesia vaccines were examined in the past for immunization against
B. canis, B. bovis, B. bigemina, or B. equi, but not B. microti (Callow, 1971; Singh et al.,
1981; Wright, 1991; Bock et al., 1992; Kung’u et al., 1992; Echaide et al., 1993;
Lawrence et al., 1993; Goodger et al., 1997; Ruef et al., 1997; Schetters et al., 1997;
Edelhofer et al., 1998; Kumar et al., 2002b; Pipano et al., 2002). Vaccine designs have
included live virulent or attenuated parasites, killed merozoites, soluble parasite
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antigens, and recombinant proteins. The first Babesia vaccine produced was developed
for B. bovis and employed an attenuated strain that was developed in splenectomized
calves (Callow, 1971; Callow, 1979; Callow et al. 1997). The success of the B. bovis
attenuated vaccines encouraged the development of attenuated vaccines for B. bigemina
and B. divergens (Echaide et al., 1993; Edelhofer et al., 1998). Immunization of
B. bigemina has incorporated the use of live attenuated or virulent organisms (Pipano et
al., 2002). Usually, the cattle are immunized when they are young because cattle
younger than 6 months display protection against developing signs of disease. At this
time, the reason for this protection is unknown. It has been suggested that antibodies
from the colostrum of an exposed mother confer protection in the calf. However,
Christensson (1987) showed that calves that do not receive colostrum still display the
same level of protection. Furthermore, Levy et al. (1982) demonstrated that the factor(s)
responsible for resistance are found in the plasma of young calves. There is more risk
involved in immunizing older animals, which don’t have the protection that younger
cattle have, so chemotherapy may be required to control the infection. This method
should only be used in endemic areas because it is only dependable for keeping the cattle
from developing clinical signs of disease, not infection. Therefore, the vaccinated
animals serve as a reservoir for infection.
Immunization with live Babesia organisms serves to benefit endemic regions such as
within Australia and Africa. There have even been some signs of cross-strain immunity.
In an experiment testing the Australian B. bovis vaccine on three calves in Malawi, all
three calves were given full protection against challenge with an African strain of
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B. bovis, despite differences between the Australian and African strains (Lawrence et al.,
1993). Regardless of the benefits of using this vaccine design, cattle that are not
continuously reinfected can clear infection, which results in dissolution of protection
from disease. Pipano et al. (2002) conducted a study of 42 Friesian cows that had been
previously vaccinated two times. They found that only 11 of 22 cows had persistent
B. bovis infection and only two of 20 cows had persistent B. bigemina infection. Besides
lack of reinfection, strain-specific resistance can result in cattle developing acute disease
to heterologous strains (Callow et al., 1967; Bock et al., 1995). Lack of reinfection and
strain variation limits the effectiveness of immunization with live Babesia organisms and
places boundaries on the movement of cattle, despite “protection”. The biggest economic
drawback to live vaccines is the limitation placed on the importation and exportation of
cattle.
Another problem associated with the live or attenuated vaccine design is the
difficulty in producing enough parasites on a large enough scale from splenectomized
calves. In Australia, vaccine producers have had to struggle to produce enough parasites
to satisfy the demand for their attenuated live trivalent tick fever vaccine containing
B. bovis, B. bigemina, and Anaplasma centrale (Standfast, 2003). Moreover, despite the
effectiveness of live attenuated vaccines, their use puts the vaccinated animal at risk for
contracting other enzootic agents, such as bovine leucosis virus, when they receive the
infected blood for the attenuated vaccine (Wright, 1991). Furthermore, attenuated
vaccines suffer a short shelf life (Wright, 1991). These shortfalls have led to research of
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alternatives such as killed vaccines, recombinant vaccines, and vaccines derived from
the soluble antigens of in vitro cultures.
A killed vaccine against equine babesiosis caused by B. equi was designed using
killed merozoites (Kumar et al., 2002b). The vaccine was prepared from B. equi infected
blood containing a lysate of 2x1010 infected erythrocytes per dose combined with the
adjuvant Quil A, followed by a booster inoculation. The vaccine was tested on donkeys,
showing protection among the vaccinated donkeys whereas the control donkeys died
from challenge. Also, the parasitemia in the vaccinated group cleared and was not
reestablished after splenectomy. These results are probably not due to the merozoite
lysate alone, as Singh et al. carried out a similar experiment reporting that the
immunized donkeys remained carriers and that parasitemia reappeared after immune
suppression (Singh et al., 1981). A major difference between the two reports was the use
of the adjuvant Quil A. Quil A is known to evoke a strong Th1 immune response, which
is why it is commonly used as an adjuvant for some viral vaccines. Also, there may have
been strain differences corresponding to less or more virulence between the strains. With
the encouraging results of the study conducted by Kumar et al. (2002b), it is surprising
that there have not been any further developments reported.
Soluble parasite antigens (SPA) have been used for a number of Babesia vaccines in
order to stimulate protection without resulting in carrier status (Goodger et al., 1987;
Goodger et al., 1992; Montenegro-James et al., 1992; Schetters et al., 1997; Schetters et
al., 2001). The antigens of SPA vaccines may be exogenous, derived from the
supernatant of in vitro Babesia-infected erythrocyte cultures, or endogenous, derived
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from Babesia-infected erythrocytes (in vitro or in vivo) that are sonically-disrupted. The
B. canis SPA vaccine, used in Europe under the name ‘Pirodog’, is made up of
exogenous antigens (Moreau et al., 1988). The vaccine limited the level of parasitemia,
the decline in packed cell volume (PCV), anemia, and splenomegaly associated with
infection (Schetters et al., 1997). However, B. canis SPA vaccine is not effective in
protecting against heterologous challenge (Schetters et al., 1995). As a result, Schetters
et al. (2001) tested the effectiveness of a B. canis canis-B. canis rossi SPA vaccine
against heterologous challenge, inducing an immune response that resulted in the
parasitemia in the vaccinates lower than in the controls.
A culture-derived endogenous B. bovis- B. bigemina SPA vaccine was tested in
Venezuela where bovine babesiosis is endemic and imported cattle suffer significant
losses (Montenegro-James et al., 1992). The vaccine reduced the incidence of clinical
disease and prevented death, however, the level of protection was not as high as with
live vaccines. Alternatively, an endogenous (as opposed to exogenous) SPA vaccine
against B. bovis was derived from a fraction of infected erythrocytes collected from
infected cattle (Goodger et al., 1987; Goodger et al., 1992). The vaccinated cows had a
lower mean daily parasitemia and survived homologous challenge, whereas the controls
had a higher daily parasitemia and did not survive challenge. Though B. bovis SPA
vaccines are protective against homologous challenge, results of heterologous challenge
have been mixed. Montenegro-James and Ristic (1985) elicited protection against
heterologous challenge using a SPA B. bovis vaccine. In contrast, Timms et al. (1983)
showed that SPA do not effectively protect against heterologous B. bovis challenge. SPA
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vaccines are safer, more stable, and easier to develop than live vaccines. However, the
protection evoked by the soluble parasite antigen does not surpass that of live vaccines
and live vaccines appear to be more dependable at this time.
Recombinant vaccines have also been explored for a number of Babesia species,
targeting fusion proteins, lipoproteins, and surface proteins. Fusion proteins are
genetically engineered to include two or more proteins or peptides. Wright et al. (1992)
selected two proteins, glutathione-S-transferase -12D3 and -11C5 (GST-12D3 and GST-
11C5, respectively), after vaccinating with fractionated crude extracts of B. bovis
parasites and purifying the protective fractions by affinity chromatography with
monoclonal antibodies. When GST-12D3 and GST-11C5 were combined and tested
against B. bovis, they elicited strong protection, but not as strong as the live vaccine.
Goodger et al. (1992) targeted B. bovis lipoprotein as a vaccine candidate because a
previous vaccine trial carried out by the author suggested lipoprotein involvement in
antibody production (Goodger et al., 1987). In order to determine if lipoprotein elicits
protective antibodies against B. bovis, calves were injected with lipoprotein (precipitated
by dextran sulphate) and then serologically tested for lipoprotein-specific antibodies and
monitored by blood smear. The vaccinated calves showed a delayed and decreased
parasitemia compared to controls (Goodger et al., 1992). The vaccinated group also
differed from controls by producing an antibody response that included high levels of
IgG1 (Th2) and IgG2 (Th1), whereas the controls remained close to baseline (Goodger
et al., 1992). However, there was not a control for the dextran sulphate, administered in
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conjunction with the lipoprotein. As a matter of fact, Diamantstein et al. (1973) showed
that dextran sulphate elicits high antibody titers.
The major surface antigens associated with the parasite apical complex, such as the
rhoptry-associated proteins, have been targeted because they play a role in host cell
invasion. Hypothetically, if the host immune system is directed to have a strong
inhibitory response to a surface protein of the apical complex, host cell invasion will be
inhibited and the parasite life cycle cannot progress. Ruef et al. (1997) targeted the
rhoptry-associated proteins for a recombinant vaccine because they are part of the apical
complex of Babesia parasites, which is involved in host erythrocyte invasion (Perkins,
1992). Rhoptry-associated protein 1 (RAP-1) was used to immunize cattle against
B. bigemina, inducing a Th1 cytokine response, but neither the specific RAP-1
antibodies nor the level of Th1 cytokines had a direct correlation with the degree of
protection against challenge (Ruef et al., 1997). Another downside to recombinant
vaccines is that the protection is short-lived, requiring continual boosts. Further, long-
term studies of boosted recombinant proteins have not been carried out.
The current vaccines have had limited effectiveness and while they may protect
against disease, they do not give full protection against future infection. Previous anti-
Babesia vaccines, such as live-attenuated or killed parasites, are usually strain-specific
and may lose their effectiveness over time because of slight natural field-strain variation.
Field investigations in Australia uncovered a nine-fold increase in the failure of the live
B. bovis vaccine to protect cattle from 1985 to 1990 due to changes in the field-strain of
B. bovis (Bock et al., 1992). At this point, it is still clear that the live vaccine is the most
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effective currently available vaccine, however, future vaccine designs should address the
need for a vaccine that is not based on maintaining a carrier status and is not strain-
specific. Such a vaccine would be more beneficial to cattle and equine industries,
allowing trade and importation of livestock in and out of endemic areas to occur more
easily.
1.7. Future focus for vaccine development
Current strategies for Babesia vaccines should incorporate a Th1 response in
addition to a Th2 immune response. A Th1 response is critical for organisms that are
intracellular because the Th2 response does not affect any intracellular stages. Antigen
presenting is an important determinant of the type of helper T cell response (Parham,
2000). In order to drive Th1 differentiation, the antigen presenting cells must be
associated with the release of interleukin-12, which are produced during the beginning
stages of infection (Avila and Calderon, 1993). The role of antigen presenting cells in
the Th2 immune response is to present the antigen to B cells. Antigen presentation to B
cells promotes differentiation into plasma cells or memory cells, which will produce
antibody to the extracellular stages of the Babesia species (Parham, 2000).
Protection in other parasitic diseases has also shown the need for a Th1 immune
response. Many chemotherapeutic and vaccine targets have effectively stimulated a Th1
immune response (Doolan et al, 1996; Das et al., 2001; Wang et al., 2004). One avenue
that has been targeted is the cathepsin L-like cysteine proteases. Research regarding the
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use of cysteine proteases in vaccines, for the most part, has shown a shift towards the
Th1 response after parasitic challenge.
1.8. Cysteine protease as a target for vaccine development
Cysteine protease inhibitors have combated a number of parasitic infections,
demonstrating that cysteine proteases are critical for survival and proliferation of
parasites (d’Oliviera et al., 1997; Engel et al., 1998; Das et al., 2001). Alexander et al.
(1998) found that inhibition of Leishmania mexicana cathepsin L-like proteases resulted
in a substantial reduction in virulence and a shift from a Th-2 to a Th-1 immune
response. Additionally, cysteine protease inhibitors have been shown to inhibit
erythrocyte invasion by Plasmodium falciparum, inhibit tissue invasion and necrosis by
Entamoeba histolytica, and block invasion of Theileria parva sporozoites into
lymphocytes (Rosenthal, 1989; De Meester et al., 1990; Syfrig et al., 1998; Greenbaum
et al., 2002). The replication and life cycle growth of parasitic protozoans and helminths
can be inhibited, without toxicity, by selectively inhibiting the cysteine protease of the
parasite (McKerrow, 1999).
Cysteine proteases have vital roles in mammalian cellular turnover and apoptosis,
but they also play a role in the life cycle of many parasites (Mathews et al., 2000; Sjid
and McKerrow, 2002). The cysteine proteases of parasites, like mammals, have catabolic
and protein processing functions. However, unlike mammalian cysteine proteases,
cysteine proteases of parasites may play a role in immune evasion, excystment/
encystment, cell invasion, and, in a few cases, tissue invasion (Sjid and McKerrow,
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2002). Accordingly, the actions of the cysteine protease(s) may differ among different
genera of parasites. The cathepsin L-like cysteine proteases can be differentiated from
other classes of cysteine proteases by conserved critical residues (Fig.1., p. 33), the
presence of cysteine-histidine-asparagine members of the catalytic triad, and an
ERFNIN-like motif in the pre-pro region. However, Sjiid and McKerrow (2002) have
found that there is still little variance between the cysteine proteases of parasites.
Cysteine proteases are not only an attractive target for vaccine and chemotherapy
designs because they play important roles in the life cycle of the parasite, but also
because they are known to elicit antibodies during natural infection. Inhibition of the life
cycles of B. equi and species of Plasmodium, Leishmania, Trypanosoma, Fasciola, and
Entamoeba has been elicited by targeting the cysteine protease. Therefore, the cysteine
proteases of B. microti may be a good target for vaccine and chemotherapy development
(Wijffels, 1994; Mulcahy and Dalton, 2001).
1.9. Babesia cysteine proteases
Holman et al. (2002) showed in vitro that inhibition of the B. equi cysteine protease
inhibits propagation of the parasites. Two cysteine protease inhibitors, E64 and E64d,
were used independently to help elucidate the activity of the B. equi cysteine protease. In
the experiment, only E64d, which is membrane permeable, brought about parasitic
inhibition. The cysteine protease inhibitor E64, which is not membrane permeable, did
not differ significantly from the controls. These results suggested that the cysteine
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protease activity is associated with intraerythrocytic functions or hemolysis associated
with merozoites leaving the erythrocyte (Holman et al., 2002).
Babesia microti encodes for two cathepsin L-like cysteine proteases, which play a
major role in life-cycle growth and cell invasion (Mahmoud et al., 2002).
1.10. Plasmodium cysteine proteases
Plasmodium falciparum expresses three papain-family cysteine proteases, known as
falcipain, that are active during the trophozoite and ring stages. At that point in the life
cycle, the cysteine proteases degrade host hemoglobin in order to provide amino acids
for parasite protein synthesis and growth (Rosenthal, 1989; Gluzman et al., 1994;
Francis et al., 1997; Rosenthal et al., 2002). After the cysteine proteases assist in
merozoite invasion of erythrocytes and hemoglobin degradation, falcipain-2 assists in
late schizont-mediated rupturing of erythrocytes to release more parasites into the blood
(by destabilizing the ankyrin-band 3 cytoskeleton of the erythrocytes). Inhibition of the
cysteine protease falcipain-2 substantially inhibits the life cycle of P. falciparum
(Rosenthal et al., 2002).
1.11. Leishmania cysteine proteases
The cathepsin L- like cysteine proteases found in all species of Leishmania are
required for the parasite life cycle and pathogenicity (Seltzer et al., 1999).
Leishmania mexicana cysteine protease plays a major role in parasitic invasion of
macrophages and intracellular survival of the parasite (Frame et al., 2000). It has also
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been shown by deletion of the entire copy of the cysteine protease gene that this enzyme
is responsible for suppressing the host Th1 immune response to L. mexicana (Buxbaum
et al., 2003). Further, Ilg et al. (1994) determined that immunization with L. mexicana
recombinant cysteine proteinase stimulates the development of a Th1 immune response.
Leishmania donovani virulence also depends on the presence of cysteine proteases.
When the cysteine protease of L. donovani was inhibited by a cathepsin B inhibitor, the
lifecycle was disrupted and parasitemia cleared (Somanna et al., 2002).
The cysteine protease activity of Leishmania species assists in the ability of the
parasite to infect and replicate in the host and appears to correlate with the degradation
of host major histocompatability complexes (MHC), which in turn cannot present
antigens to B cells or T cells, inhibiting the host immune response (Descoteaux, 1998;
Courret et al., 2001). Consequently, inhibition of the cysteine protease genes by
homologous recombination results in loss of Leishmania pathogenicity (Selzer et al.,
1999). Therefore, the cysteine protease of Leishmania species has been seen as an
attractive target for vaccine development. BALB/c mice vaccinated with purified
cysteine protease, exhibited protection against L. major infection following parasite
challenge (Rafati et al., 2000, 2001).
1.12. Trypanosoma cysteine proteases
Leishmania and Trypanosoma species have similar cysteine proteases that are
characterized by an unusual 100 amino acid C-terminal sequence. Mutant Leishmania
and Trypanosoma species lacking the cysteine protease have a reduced infectivity of
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macrophages in vitro and in BALB/c mice (Alves et al., 2001). Cruzipain, the major
cysteine protease of Trypanosoma cruzi, has vasodilatory activity, which is brought
about by cruzipain release of kinins. The kinins induce plasma leakage, which allows T.
cruzi to escape from the blood vessel into nearby tissues (Mulcahy and Dalton, 2001).
A DNA vaccine encoding cruzipain induced protective Th1 cytokines (IFNg) and
cytotoxic T lymphocytes in a mouse model (Schnapp et al., 2002a). Further, the authors
showed that vaccination of mice with the DNA vaccine encoding cruzipain evoked a
significant level of protection against T. cruzi and Th1 cytokines including IFNg and
IL-12 (Schnapp et al., 2002b).
1.13. Babesia vaccine design
Babesia species like other parasitic protozoans, such as Plasmodium, Leishmania,
Trypanosoma, and Entamoeba, and parasitic helminths, such as Fasciola species, encode
similar cathepsin L-like cysteine protease(s), which may play a key role in immune
evasion, virulence, and invasion into tissue as well as the cell (Rosenthal, 1989; Keene et
al., 1990; Avila and Calderon, 1993; Gluzman et al., 1994; Francis et al., 1997;
Alexander et al., 1998; Descoteaux, 1998; Frame et al., 2000; Cordova et al., 2001;
Greenbaum et al., 2002; Holman et al., 2002; Mahmoud et al., 2002; Rosenthal et al.,
2002; Sjid and McKerrow, 2002). Cysteine proteases have been targeted for vaccines
and chemotherapy against Babesia, Plasmodium, Leishmania, Trypanosoma,
Entamoeba, and Fasciola species, resulting in inhibition of the parasite life cycle (Healy
et al., 1976; Rosenthal, 1989; Wijffels, 1994; Oliaro and Goldberg, 1995; Engel et al.,
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1998; Selzer et al., 1999; Rafati et al., 2000; Rafati et al., 2001; Bangs et al., 2001; Das
et al., 2001; Mulcahy and Dalton, 2001; Holman et al., 2002; Rosenthal et al., 2002;
Schnapp et al., 2002a-b).
The vaccine designed for this study targets a protein in B. microti shown to be
critical to in vitro replication of B. equi (Holman et al., 2002; Mahmoud et al., 2002).
Babesia microti cysteine protease-1 was selected because, of the two-cysteine proteases
identified in B. microti, it is most similar to the characterized B. equi cysteine protease.
Therefore, a vaccine designed with the B. microti cysteine protease-1 will make a better
model for B. equi.
 The vaccine design encompasses a prime boost of plasmid DNA with the B. microti
cysteine protease-1 (Bmcp) insert, followed by two boosts of cysteine protease-1 peptide
(CP) or two boosts of plasmid DNA with Bmcp-1 at two-week intervals. It has been
shown that the prime-boost strategy can enhance the immunogenicity of the plasmid
DNA vaccine (Sedegah et al., 2000; McConkey et al., 2003; Rainczuk et al., 2003;
Ramiro et al., 2003; Sedegah et al., 2003; Wang et al., 2004). In a study by Rainczuk et
al. (2003), the mice that were boosted with recombinant protein had a significantly
higher rate of survival against Plasmodium chabaudi adami challenge when compared to
the controls, in addition to exhibiting higher IgG2 levels (Th1) and lower IgG1 levels
(Th2) than mice that were only primed with the plasmid DNA. The host immune
response to plasmid DNA vaccination involves the uptake of DNA by host cells
followed by antigen presentation on the cell surface and uptake by antigen presenting
cells (APCs). The specific immune response is then determined (Mumper and Ledebur,
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2001). It is anticipated that Bmcp will be taken up by the host cells and presented as
antigen on the cells, to be taken up by APCs, stimulating primarily a Th1 immune
response and secondarily a Th2 response. DNA-based vaccines have the ability to
encode antigens to induce both CD4+ and CD8+ T cells and, therefore, the ability to
elicit humoral and/or cell-mediated immunity against parasitic infections. A DNA
vaccine against Plasmodium yoelii, encoding the circumsporozoite protein (CS), elicited
high levels of CS-specific antibody and CD8+ T cells, resulting in a protection rate of
68% (Sedegah et al., 1994). Plasmid DNA has been used as a vector of antigen to
immunize against numerous parasitic infections, displaying protection against multiple
species of Plasmodium, Leishmania, Theileria, Trypanosoma, and Fasciola (Sedegah et
al., 1994; Xu and Liew, 1995; Doolan et al., 1996; d’Oliveira et al., 1997; Montgomery
et al., 1997; Alarcon et al., 1999; Sepulveda et al., 2000; Smooker et al., 2000; Kumar et
al., 2002a). Another benefit is that the immune response to DNA vaccines is usually long
lasting (Alarcon et al., 1999).
The vaccine design in this study utilizes intramuscular (i.m.) injection for priming
with the pDNA with Bmcp-1 insert. It was previously demonstrated by Wolff et al.
(1990) that i.m. vaccination with plasmid DNA encoding an inserted protein will result
in uptake and expression of the encoded protein by mouse skeletal muscle cells. Also,
the plasmid DNA is taken up without integrating into the mouse genomic DNA, existing
in the cells in an extrachromosomal form. Wolff et al. (1992) further found that i.m.
injection of plasmid DNA also has long-term expression, as shown by the presence of
foreign genes in the muscle of mice for at least 19 months following injection. Thus, i.m.
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injections of pDNA can be a safe and effective method for expressing and presenting
parasite antigens to evoke an immune response by the host (Montgomery et al., 1997).
In this study, the plasmid DNA (pDNA) encoding the cysteine protease will be
injected i.m., after which it is anticipated that the Bmcp-1 protein will be expressed
extracellularly and taken up by APCs. The APCs will then stimulate an immune
response that is aimed towards inhibiting the cysteine protease when the host mouse is
challenged by infection with B. microti. Targeting the cysteine protease will
hypothetically keep the parasite from being able to invade the host erythrocytes,
inhibiting the parasite from following a normal life cycle, resulting in a reduced
parasitemia. If successful, this vaccine strategy may be applicable to B. equi, which has
similar cysteine proteases. Successful application would also stimulate interest in
determining whether other economically important Babesia species encode for cysteine
proteases that might be targeted in recombinant vaccines.
1.14. Hypothesis
Vaccination of mice with pDNA with Bmcp1 insert and the gene products will elicit
a protective immune response in BALB/c mice against B. microti challenge when
administered using a prime-boost strategy.
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2. MATERIALS AND METHODS
2.1. Preparation of pDNA with Bmcp1 insert and pDNA without insert
 The Bmcp1 gene was previously inserted into the entry vector (pENTR-His-ccdB;
Parr and Ball, 2003). Transduction of the entry vector with the destination vector, pYES-
DEST52 (pYD52), resulted in pYD52 with the Bmcp1 gene insert. To ensure proper
recombination, the resulting plasmid was transformed into DH5a competent cells. When
the transformation was plated on LB plates with 100 mg/ml ampicillin (15 h, 37 ºC), only
colonies of the DH5a cells with pYD52 with the Bmcp1 insert were capable of growth
because the new attB recombination sites form a site for ampicillin resistance. If
transformation failed, pENTR with the gene insert would not have been capable of
growth because it does not have ampicillin resistance and pYD52 would not have been
capable of growth because of the intact ccdB site that inhibits gyrase, which is necessary
for DH5a growth. To reconfirm the presence of the Bmcp1 insert, multiple colonies
were selected and polymerase chain reactions (PCR) were performed using forward
degenerate primer CPD3FT (5’-TG(CT) GG5 (AT)(GC)5 TG(CT) TGG GC-3’) and
reverse primer SD3prime (5’-CAA CGG CAT TAA ACC GAA TT-3’) (Gene
Technologies Laboratory, Institute of Developmental and Molecular Biology, Texas
A&M University, College Station, Texas), with locations indicated in Fig. 1. PCR was
performed in 20 ml volume containing 50-100 ng of the template DNA, 1 pmol of each
primer, 5 mM KCl, 1 mM Tris HCl, pH 8.3, 1.5 mM MgCl2 and 0.4 U TAQ polymerase.
Negative controls included all but the template DNA. Amplification was carried out in a
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thermocycler (Express or Sprint Thermal Cycler; Hybaid, Middlesex, United Kingdom)
using a hot start method (94 ºC for 10 min). The amplification process consisted of
initial denaturation at 94 ºC for 10 min; 30 cycles of 94 ºC denaturation for 1 min, 55 ºC
annealing for 1 min, 72 ºC extension for 1 min; final 72 ºC extension for 10 min,
followed by a hold at 4 ºC.  All PCR products were electrophoresed through 1% agarose
gels, stained with ethidium bromide and visualized by UV transillumination to confirm
the expected 700 bp size of the PCR product.
  The pDNA without the Bmcp1 gene insert (empty pDNA), was prepared by
transformation of E. coli DB3.1 competent cells by the pYD52 destination vector, which
confers ampicillin resistance to the E. coli. Unlike other strains of E. coli, DB3.1 cells
possess a gyrase mutation, which allows growth despite the presence of the ccdB gene.
The transformation was then plated on LB plates with 100 mg/ml of ampicillin and
incubated for 15 h at 37 ºC.
The pYD52 with Bmcp1 in DH5a E. coli and the empty pYD52 in DB3.1 E. coli
were propagated by inoculating a single PCR positive colony into 6 ml of LB medium
with 100 mg/ml ampicillin at 37 ºC with shaking (250 rpm) for 8 h, followed by sub-
inoculation of 0.3 ml of the most turbid cultures into 149.7 ml of LB medium with
100 mg/ml ampicillin at 37 ºC with shaking (220 rpm) for 16 h. Some of the culture that
was sub-inoculated was also cryopreserved as stock in 50% glycerol (flash frozen in
liquid nitrogen for 30 sec. and then stored at –80 ºC).
After the cultures incubated for 16 h, Qiagen HiSpeed Plasmid Maxi Kits (Qiagen)
were used to purify pYD52 with Bmcp1 from DH5a cells and empty pYD52 from
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DB3.1 cells, according to protocol for future use in animals (Qiagen 12662). All batches
of purified pYD52 with Bmcp1 were pooled, as were the batches of empty pYD52, and
the DNA concentrations of the respective pools were determined by spectrophotometry
(Biotech Photometer UV 1101, WPA). A sample of purified pYD52 with Bmcp1 was
sequenced with primers located within the vector, forward primer BmPDF (5’-TAG
CAG CTG TAA TAC GAC TC-3’) and reverse primer BmPDR (5’-AAC TCA ATG
GTG ATG GTG-3’) (SIGMA- GENOSYS, The Woodlands, Texas) to confirm presence,
direction, and proper frame of the insert (DNA Technologies Core Lab, Department of
Veterinary Pathobiology, Texas A&M University, College Station, Texas).
The purified pDNA was ethanol precipitated and resuspended in the minimum
amount of ultrapure water required for resuspension. The final concentration was
determined by spectrophotometry and the pDNA was stored at –20 ºC until it was used.
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Fig.1. Amino Acid Sequence of Babesia microti Cysteine Protease-1 Gene (CP-1)
and Cysteine Protease Peptide (CP). Deduced amino acid sequences from Babesia
microti cysteine protease genes aligned by Holman et al. (2002) with those of B. equi
and Theileria annulata (GenBank Accession Nos. AF036251 and M86659). Residues of
the S1 subsite (catalytic triad members) are indicated by the numbers 1-4, critical
cysteine residues are bold and underlined, and S2 subsite residues (substrate specificity)
are indicated by the numbers 5-12. Gaps were introduced to facilitate alignment (-).
Residues conserved between B. microti and either T. annulata or B. equi are in bold
type. Residues of the ERFNIN-like sequence in the proregion are in bold and double
underlined. The CP sequence is highlighted. Locations of the PCR primers used to
determine presence of the cysteine protease in pYD52 are indicated.
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Theileria annulata M T V L D D H F P Q G D D E T V V P T S S S I P I L S Q M R Q I V I K K R L - -
Babesia equi Cys1 M V A V I S A N P S E R L M D N R I D D D V E V A E E Q T S F F R R L F A K R R
B. microti CP1 M A T D L K L L G S E P L S R S E T E A D L G H V S S S K F K F K S Y F F K A I
B. microti CP2 M D A E F D S L N N I A I Q R M A K I E N D M H E I I V S D F P N G G L H N T K
Theileria annulata L I S F L L T F - F I L A L S S A S I L T Y F F F R S K S I T N F K S L A I E
Babesia equi Cys1 N V I F L S A V S F I V L V L A S T L T G V F V A R H R A V V A F K E N L T Q
B. microti 1  - - S F L K T Y K F Y S I L A A S A I A I A T - F I V I L I V A F Y E T E A S
B. microti 2 Y I S E D T I S Y N L E T R G T I N A D N T L G S K D I S I Q S - N E I N N K
Theileria annulata - - - - - H I E S H Y P S M D P S K R A G F V E E I V K I R Q T G K I T S D A 
Babesia equi Cys1 - - - - - F L D E K F A L T E P K E R A S H V E E L T D L F S N G Y I S A D H
B. microti 1 R Q V K A R L I D D M L S G Q S L Y N C Y P Y D Q Q R Y H V G K P A Q K P E S
B. microti 2 I L Q L E K I S K F S K D Y S L K S R V S T S K I I M L S E I G G I L N E V V
T. annulata  - - - - - - - - - E S E L D M L I E F D A F V E K Y K K V H R S F D Q R V Q R F
B. equi Cys1 - - - - - - - - - V S E L E A L M E F D E F N K F Y S R E H A D A D E R R V R F
B. microti 1 V G E F I V R T L T E H G Y T I D P D L E A K   I Y K E F N I F M A K F G K I Y F
B. microti 2 - K I D K D F D P I D E A N I I V N F K L Y A S E Y N R V F D S N S D F V N R Y
T. annulata L T F R K N Y H I V K T H K P - - - - - - - - - - - T E P Y S L D L N K F S D
B. equi Cys1 L A F R D N Y N A V K A Q T G - - - - - - - - - - - E E S   Y   E K G I N K F S D
B. microti 1 T P K E K G D K Y I N F R K S Y E I V M A H N N N K N V S Y K M A L G Q F S D
B. microti 2 M I F R N N F I E I K T H N A - - - - - - - - N P K K T Y T K G I Q W Y F S D
T. annulata L S D E E F K A L Y P V I T P P K T Y T S L S K H L E F K K M S H K N P I Y   I
B. equi Cys1 M T D E E F N L R F P A L S V E E L K K S L E V S A S E E F T S - - - - - P E
B. microti 1 K S P E E F E N S V L N P M T S N E H Y V N A I K S G R F N L F - - - - - - -
B. microti 2 N R S D S E I N N I L S T  N F A D V A P N L R S L E E I S T P R E F L K E K V G
T. annulata S K L K K A K G I E E I K D L S L I T G E N L N W A R T D A V S P T K D Q G D H
B. equi Cys1 H L D K V R I A K G L G V E D S V D - G E D L D W R K L N G V T P V K D Q G N -
B. microti 1 - - - - - - - - - R P D P R Q E G I - P  E Q F I  W D H K F L G - P V L N Q G A -
B. microti 2 - - - - – - - - - - - - V T V V - D V K E R  F D W R D Q D V I S P V R A Q P G -
  
T. annulat a C G S C W AF S S I A S V E S L Y R L Y K N K S Y F L -  S  E Q  E L V N C D K S S   M
B. equi Cys1 C G S C W AF A A V G S V E S L  Y L I K  - K G Q  A L D L  S  E Q  E  L V N  C  E E N S   N
B. microti 1 C G S C W AF A T A G A V Q S L  F N I V  N N - S  K L V L  S P Q  E  L V D  C  T I N A   N
B. microti 2 C G R C W AI A A A G A I D A V  Y N I K  N K G S  K M I T  S P Q  H  L M N  C  V S D E   F
                   1
T. annulata G  C A - G G L P I T A L E Y I H S K G  - V S F  E S E V  P Y T G  I V S P  C K P S I   K
B. equi Cys1 G C E - G G L P N K A L E Y I K A K G - I S H S K E L P Y H A A N E E C V V S S  S
B. microti 1 G C K - G G N P I Y A F N Y V R D H G - L C T L N D Y P Y V G F Q Q K C S S S S  C
B. microti 2 T C Q T G G V V R M A I E Y A Q V K G G V C V E S D V P Y V A E K Q K C E T K A  C
                       5 6
T. annulataN - - K V F I D S I S I L K G N D V V N K S L V I S P T V V G I A V T K E L K L Y  S
B. equi Cys1 - D K V F I H S F F A N T G L D I L N K S L V V S P T I V A   L A V S K E F T A Y  K
B. microti 1 K H K I P I K N K M L V T S G F D I A L A Q G - S P M V V G I D A N G P F Q H Y  S
B. microti 2 K Q L V T I S K Y F K V P A N K M Q S V L K D K G P I A A A M A I T K D F L Q Y  E
7     8
T. annulata G G I F T G H C G G E - L N H A V L L V G E G V D H E T G M  R Y W I    I    K  N  S  W
B. equi Cys1 G G I F T G E C A P E - L N H A V L L V G E G  H D E A T G K  R F W I    V  K  N  S  W
B. microti 1 H G I F E AP C T P G T S N H A V L L V G Y G V D K E T G K K Y W V  I    K  N  S  W
B. microti 2 S G V Y N G S C N K V - L N H A M L I T G Y G Y D D S V N S R Y W I F K N S W
   9     2 10   11                                                          3   4
T. annulata G E  D W G E N G F L R L Q R T K K G L D K C G I L T - F G L N P I L Y S S ;
B. equi Cys1 G T D W G E N G F F R L E R T D E G S D K C D I L E - F G F T P A L K C H S K K   L
B. microti G P D W G E K G Y A R I L R S D D G N G A D C N L T K F G L M P L;
B. microti 2 G S N W G K D G Y V Y V S R D T E H K D S F C Q I N L A P Y V A V M ;
12
--CPDFTÆ
¨SD3prime--
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2.2. Bmcp1 peptide (CP)
A peptide derived from Bmcp1 (CP) (Fig. 1) was synthesized by
fluorenylmethoxycarbonyl (Fmoc) solid-phase chemistry employing a Millipore 9050
Plus (Perceptive Biosystems) automated synthesizer and purified by the Peptide
Synthesis Core Facility, Department of Veterinary Pathobiology (Dr. Judith Ball).
2.3. Vaccine preparation
The pYD52 with Bmcp1 and empty pYD52 were adjusted to a final concentration of
2 mg/ml with Dulbecco’s phosphate buffered saline (PBS, pH 7.4) (Sigma) just prior to
inoculation. The peptide boost was prepared by resuspending the synthetic peptide CP in
PBS (3:4 ratio by volume) and then adding Sigma Alhydrogel (13 mg/ml) (1:4 ratio by
volume) to a final concentration of 2 mg/ml. The suspension was incubated at 4 ºC while
turning on a DYNAL‚ Rotamix for 12 h. The control for the CP peptide was prepared
in the same manner as described above, excluding CP. The experimental controls
received PBS only.
2.4. Injections and vaccine trial procedure
Female BALB/c mice (Harland Labs, Houston), 3-5 months of age, were used for the
vaccine trials. Two vaccine trials were carried out, each consisting of five groups of four
BALB/c mice. The five groups represented: 1) pYD52 with Bmcp1 (pYD52/Bmcp)
followed by two pYD52/Bmcp boosts, 2) pYD52/Bmcp followed by two CP/Alhydrogel
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boosts, 3) pYD52 without an insert (pYD52) followed by two pYD52 boosts, 4) pYD52
followed by two boosts of Alhydrogel only, and 5) PBS followed by two boosts of PBS.
Primary inoculations were administered intramuscularly under anesthesia. The mice
were anesthetized individually prior to receiving the intramuscular injection (i.m.) of
either 50 ml of pYD52 with Bmcp1 (100 mg), 50 ml of empty pYD52 (100 mg), or 50 ml
of PBS into the thigh muscle. The anesthetic agent, isoflurane, was administered by
inhalation using an induction chamber and anesthesia was maintained during the
injection by inhalation through a facemask. All injections were administered using 30
gauge, 0.5cc syringes (ReliOn®). Boosts were administered subcutaneously (s.c.) and
consisted of either 50 ml of pYD52 with Bmcp1 (100 mg), 50 ml of empty pYD52 (100
mg), 50 ml of CP (100 mg), 50 ml of the control for the peptide, or 50 ml of PBS. The first
boost was administered two weeks after the primary inoculations, followed by the
second boost two weeks later. Three weeks after the second boost, all mice were
challenged with B. microti parasites by intraperitoneal inoculation. Three days prior to
challenging the mice, the pre-challenge packed cell volume (PCV) was determined and
plasma was collected. The PCV of each mouse was determined by collecting blood from
the tail tip in heparinized microhematocrit capillary tubes (Fisherbrand®, Pittsburgh,
PA), followed by centrifugation for 30 sec. (IEC MB micro hematocrit centrifuge). The
mice in the first vaccine trial received a direct inoculation of 2x107 B. microti infected
erythrocytes, which were previously maintained by sub-passage in BALB/c mice until
used for the live challenge. The mice in the second vaccine trial received 105 infected
erythrocytes.
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2.5. Analysis of infection
The infections were monitored daily by blood smears of blood drawn from the tip of
the tail. The smears were methanol-fixed and then Giemsa-stained for microscopic
examination at 1000X under oil immersion. Parasitemias were monitored by counting
the number of B. microti-infected erythrocytes among 1000 erythrocytes. PCV was also
determined at key points during parasite challenge such as when parasitemia began to
rise, when parasitemia began to drop, and when mice recovered from parasitemia
(corresponding to days 7, 11, and 23 for the first vaccine trial, and days 12, 15, and 28
for the second vaccine trial). After the parasitemia cleared, as determined by three
consecutive days without parasite observation in blood smears, the mice were humanely
euthanized. Euthanasia was carried out by placement in a CO2 chamber, directly
followed by cardiac puncture to exsanguinate the mice. Blood was collected into EDTA.
Mouse plasma was collected after centrifugation of the blood at 1200 rpm for 20 minutes
(Jouan GR412). The plasma was then stored frozen at –80º C until analyzed. The plasma
collected from the second vaccine trial was analyzed by enzyme-linked
immunoabsorbant assay (ELISA) in order to detect specific antibody activity to Bmcp1.
2.6. ELISA
Microtiter plates were precoated (75 ml/well) with a solution of Poly-L-Lysine
(Sigma P2636, St. Louis, MO) in bicarbonate buffer (final pH and concentration, 9.6 and
1.6 ml/ml, respectively) and incubated for 1.5 h at room temperature (RT). The plates
were washed one time with PBS/Tween-20 (0.05% Tween-20, Sigma P1379). The plates
37
were then coated (75 ml/well) with 1% glutaraldehyde (Sigma G5882, grade 1) and then
incubated at RT for 13 min. The plates were then washed one time with wash solution
(Tween-20 in 1M NaCl, 0.05% Tween-20 final concentration).
The antigenic substrate, CP peptide, was diluted to 10 mg/ml in PBS and 75 ml were
added to each well except negative control wells with PBS only and positive control
wells with mouse NSP4 peptide. The plates were sealed and incubated overnight at RT.
The next day, the plates were rinsed twice with wash solution.
Non-specific binding was blocked by first adding 200 ul of 1M glycine in PBS to
each well, and incubating for 1 h 45 min at 37 ºC. Then, the solution was flicked out of
the plates and 200 ml of a 1:1 mixture of 5% blotto (non-fat dry milk in PBS) and 1%
gelatin was added to each well and the plate incubated for 1 h at 37 ºC. The solution was
shaken from the plates.
Starting dilutions of 1:25 were prepared for the pre- and post-vaccination plasma of
each mouse in 5% blotto. The starting dilutions of the pre- and post-vaccination plasma,
positive control, and negative control were carried through six serial 2-fold dilutions,
with a final volume of 75 ml/well for each dilution.
The standard positive and negative control sera used for the test were the pre- and
post-sera of mice inoculated with NSP4 peptide developed and previously tested by the
Peptide Synthesis Core Facility, Department of Veterinary Pathobiology (Dr. Judith
Ball). An additional control was 5% blotto as primary antibody. The plates were
incubated for 1 h at 37 ºC. The solution was shaken out of the plates and the plates were
washed seven times with wash solution.
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The second antibody, Horse Radish Peroxidase (HRP)-conjugated anti-mouse
antibody, was diluted 1:5000 in 5% blotto and 75 ml were added to all wells and then the
plates were incubated for 1 h at 37 ºC. The solution was shaken out and the plates were
washed seven times with wash solution. Tetramethylbenzadine substrate (Pierce) was
added to every well (100 ml/well), incubated 8-10 min at RT, and then the reaction was
stopped by adding 100 ml of 2M sulfuric acid (H2SO4) to every well. The absorbance
was read at 450 nm.
2.7 Statistical analyses
Student’s t-test was used to compare the mean parasitemias, PCVs, antibody titers,
time to peak parasitemia, and time from peak parasitemia to clearance of the parasite
from blood smears. P-values ≤ 0.05 are considered statistically significant.
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3. RESULTS
3.1 Vaccine Trial I
3.1.1. Parasitemia
The mice in the first vaccine trial were challenged with 2 x 107 B. microti-infected
erythrocytes. Infected erthrocytes were observed in Geimsa-stained blood smears of all
mice beginning on day 2 post-challenge, after which 10 to 20 days lapsed before
parasites were no longer detected microscopically (Fig. 2). One mouse in the control
group that received pYD52 with two boosts of Alhydrogel showed a significantly lower
parasitemia (P< 0.05) than any other mouse in Vaccine Trial I. This mouse was therefore
considered an outlier and was not included in statistical analysis. No statistically
significant differences were found between the peak parasitemias of any of the
experimental groups when compared to the appropriate controls (P> 0.05, all group
comparisons). The highest and lowest mean peak parasitemias were observed in
experimental groups. The highest, 40.5%, was observed in the experimental group that
received pYD52/Bmcp with two CP/Alhydrogel boosts. The lowest mean peak
parasitemia, 30.7%, was observed in the experimental group that received pYD52/Bmcp
with two pYD52/Bmcp boosts. This latter group was also determined to be clear of
B. microti (recovered) two to three days before all other groups, as determined by three
consecutive days of blood smears with no microscopically detectable parasitemia. All
mice recovered within 19 days of being challenged.
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3.1.2. PCV
The mean PCV of all vaccine trial groups decreased from day 0 to day 7 at a rate of
approximately 1% per day (Fig. 3). From day 7 to day 11, the mean PCV dropped
dramatically, approximately 2.5% per day for all groups (Fig. 3). The dramatic drop in
PCV between days 7-11 correlates with the mean peak parasitemias for all groups,
which occurred on day 9 (Fig. 3). The PCVs of the experimental groups, pYD52/Bmcp
with two CP/Alhydrogel boosts and pYD52/Bmcp with two pYD52/Bmcp boosts, were
not significantly different from those of the controls (p>0.05). The group that showed the
least drop in PCV was the control group that received pYD52 with two pYD52 boosts.
The group that showed the greatest drop in PCV was the control group that received
pYD52 with two boosts of Alhydrogel/PBS. After the mice appeared to be clear of
parasitemia, a final PCV was determined. The experimental group that received
pYD52/Bmcp with two pYD52/Bmcp boosts showed the PCV returning to normal levels
at a faster rate than all other groups (Fig. 3). The PCVs of the control group that received
pYD52 with two boosts of Alhydrogel/PBS remained lower than all other groups (Fig.
3).
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Fig.2. Vaccine Trial 1: Average Group Percent Parasitemias
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Fig.3. Vaccine Trial 1: Average Group Packed Cell Volume (PCV)
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3.2. Vaccine Trial II
3.2.1. Parasitemia
The mice in vaccine trial II were challenged with 105 B. microti-infected erthrocytes.
B. microti-infected erthrocytes were observed in Geimsa-stained blood smears of all
mice beginning 4 to 7 days post-challenge, after which 15 to 21 days lapsed before
parasites were no longer detected in blood smears  from the mice (Fig. 4). Parasites were
detected in two control groups, the control pYD52 with two pYD52 boosts and the PBS
control group, 1 and 3 days respectively, before parasites were detected in other groups.
One mouse in each of the 5 groups showed either no parasites or a significantly lower
parasitemia in the blood smears, when compared with mice in the same group or in
vaccine trial II as a whole (P< 0.05). These mice were therefore considered outliers and
were not included in statistical analysis. The experimental control group that received
pYD52 with two boosts of pYD52 was the only group with parasitemias significantly
different from other groups. This group had a significantly lower mean peak parasitemia
than the experimental group that received pYD52/Bmcp with two pYD52/Bmcp boosts
(P< 0.05) and the control PBS group (P< 0.05). The highest mean group peak
parasitemia, 18.2 %, was observed in the experimental group that received pYD52/Bmcp
with two pYD52/Bmcp boosts. The lowest mean group peak parasitemia, 13.6 %, was
observed in the control group that received pYD52 with two boosts of pYD52. All mice
recovered within 25 days of being challenged.
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3.2.2. PCV
From day 0 to day 12, the mean PCV of all the groups, except the group that
received pYD52/Bmcp with two pYD52/Bmcp boosts, decreased at an average rate of
1.4 to 1.7 % per day (Fig. 5). The PCV of the group that received pYD52/Bmcp with
two pYD52/Bmcp boosts decreased at an average rate of 0.8% per day. From day 12 to
day 16 post-challenge, the mean PCV dropped for all groups except the PBS group. The
PCV of the PBS group increased at a rate of 1% per day from day 12 to day 16. The
PCV of the group that received pYD52/Bmcp with two pYD52/Bmcp boosts increased
at a rate of 1.5% per day from day 12 to 16, while the PCV of the remaining groups
increased at rates ranging from 0.25% to 0.75%. The low PCV values determined on day
12 correspond to the time when the mice were experiencing rising parasitemias near
peak parasitemias. The rising PCV values determined on day 16 correspond to the time
when the parasitemias of the mice were declining. The dramatic drop in PCV between
days 7-11 correlates with the mean peak parasitemias for all groups, which occurred on
day 9, post-challenge. The group that received pYD52 with two pYD52 boosts showed
the least drop in PCV. The group that received pYD52 with two boosts of
Alhydrogel/PBS showed the greatest drop in PCV. After no parasites were detectable
microscopically in the mice, a final PCV was determined. The experimental group that
received pYD52/Bmcp with two pYD52/Bmcp boosts recovered at a faster rate than all
other groups (1.75% per day). The final PCV of all groups ranged between 50 to 52 %,
compared to 57% at the outset of vaccine trial II (Fig.5).
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 Fig.4. Vaccine Trial 2: Average Group Percent Parasitemias.
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Fig.5. Vaccine Trial 2: Average Group Packed Cell Volume (PCV)
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3.2.3. ELISA
The pre- and post-plasma samples from each mouse were negative for B. microti
cysteine protease-specific antibody at all dilutions tested. The titer for the positive
standard control was observed at 1:250 for each test. The negative standard control for
the cysteine protease antigen and all plasma samples from the control mice were
consistently negative. The standard positive and negative controls functioned properly,
thus, the ELISA was carried out without error.
NOTE: The plasma samples from the first vaccine trial were not analyzed because
they were deemed unfit for analysis after they were heated for an unknown amount of
time in a broken freezer (The inside of the freezer was hot to the touch and condensation
was observed on the lids of the samples).
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4. DISCUSSION AND SUMMARY
Babesia species have a worldwide distribution, affecting a wide range of mammalian
hosts (Levine, 1985). The major route of transmission is through the bite of an infected
Ixodid tick, however, other routes of transmission could include transplacental,
intrauterine, blood transfusion, organ transplant, or blood transfer during fighting
(canids) (Neitz, 1956; Du Plessis and Basson, 1966; Levine, 1985; Errsenio-Jenssen et
al., 1987; de Vos et al., 1994; Taboda, 1997; Phipps and Otter, 2004). Babesia species of
major economic importance are those that cause equine and bovine babesiosis.
Equine babesiosis threatens the importation and exportation of horses and decreases
the performance of horses. The United States is at risk of infection coming in from
Florida, where approximately 10,000 horses are imported and exported every year. The
first outbreak of equine babesiosis in the United States occurred in Florida in 1959, after
infected horses were imported from Cuba (Holbrook, 1969; Knowles, 1998). The
outbreak resulted in the death of 20% of the infected horses and $5 million in losses.
Bovine babesiosis caused major economic losses in the 1860’s, when B. bigemina
and B. bovis caused the death of over 15,000 head of cattle, in addition to weight loss
and decreased milk production (Smith and Kilborne, 1893; Marquart et al., 2000). If a
similar outbreak occurred in the United States today, the economic losses would amount
to over a billion dollars. In order to eliminate bovine babesiosis from the United States,
the Cattle Fever Tick Eradication Program (CFTEP) was put into action in the late
1800’s. This program effectively cleared the United States of B. bigemina, B. bovis, and
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the vector tick by mandatory dipping of all cattle in the southern United States. Today,
the United States is threatened by the possible reintroduction of Boophilus ticks. The risk
of establishment of tick populations is increased by the development of acaricide
resistance among Boophilus populations (Corson, 2001). CFTEP “tick riders” still
monitor the border between the United States and Mexico, which is endemic with
B. bovis- and B. bigemina-infected Boophilus ticks, to apprehend stray livestock coming
into the United States from Mexico. Stray and smuggled animals from Mexico can carry
infected ticks. A report in 2000 noted that 50% of the cattle and 20% of the horses seized
during smuggling attempts into the United States were infested with Boophilus ticks
(Bowers, 2000). In addition, deer carrying infected ticks also pose a risk as they freely
move from Mexico to the United States.
Another Babesia species of growing concern in the United States is B. microti, the
primary cause of human babesiosis (Gorenflot et al., 1998). Within the last decade, the
frequency of diagnosed cases has increased (Kjemtrup and Conrad, 2000). Clinical
profiles of human babesiosis can range from asymptomatic to highly pathogenic and
fatal. The degree of parasitosis is directly related to the efficiency of the host immune
response, which can be inhibited by concurrent infection or splenectomy (Gorenflot et
al., 1998).
In order to fight infection with Babesia, it is important for the host to mount both a
cellular and humoral immune response. A humoral immune response is responsible for
eliciting IgG to bind and label extracellular parasites for elimination during the early
stages of infection, and later in infection, the humoral immune response stimulates
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specific antibodies to the Babesia species (Goodger et al., 1992; Parham, 2000). The
cellular immune response, specifically CD4+ T cells and the subsequent release of IFN-
g, are important for attacking intracellular parasites (Ikuo et al., 1994; Shimada et al.,
1996). Together, cellular and humoral immune responses can help clear infection and
protect against re-infection (Parham, 2000; Aguilar-Delfin et al., 2003).
Vaccines have been developed against a number of Babesia species with variable
success (Callow, 1971; Singh et al., 1981; Wright, 1991; Bock et al., 1992; Kung’u et
al., 1992; Echaide et al., 1993; Lawrence et al., 1993; Goodger et al., 1997; Ruef et al.,
1997; Schetters et al., 1997; Edelhofer et al., 1998; Kumar et al., 2002b; Pipano et al.,
2002). Vaccine designs have included live virulent or attenuated parasites, killed
merozoites, soluble parasite antigens, and recombinant proteins. Attenuated vaccines
have been developed for bovine Babesia species, using the method of premunization,
resulting in cattle that are protected against disease but must remain carriers for life in
order to maintain protection (Callow, 1971; Callow, 1979; Echaide et al., 1993; Callow
et al. 1997; Edelhofer et al., 1998; Pipano et al., 2002). Therefore, the attenuated vaccine
design serves to benefit regions of the world that are endemic with the infected-tick
vector so infection is maintained in the herd. The downsides of the attenuated vaccine
are that only endemic regions benefit, it is difficult to produce in a large scale, has a
short shelf life, the blood-based vaccine may carry other pathogens, and it is strain-
specific (Callow et al., 1967; Wright, 1991; Bock et al., 1995; Pipano et al., 2002;
Standfast, 2003).
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Killed merozoite vaccines were developed to protect against B. equi, but vaccine trial
studies have had mixed results (Singh et al., 1981; Kumar et al., 2002b). Soluble parasite
antigen- and recombinant protein- based vaccines have shown promise and are safer,
have a longer shelf life, and are easier to develop than live vaccines (Goodger et al.,
1987; Goodger et al., 1992; Montenegro-James et al., 1992; Schetters et al., 1997;
Schetters et al., 2001). However, the protection evoked is not as dependable as with live
vaccines and may require continual boosting.
The need for a vaccine that avoids a carrier state or strain specificity and induces a
Th1 and Th2 immune response is evident. Such a vaccine would be beneficial to bovine
and equine industries, allowing trade and importation of livestock in and out of endemic
areas to occur more easily. Vaccine designs for some other parasites have targeted
cysteine proteases, which may play a role in immune evasion, excystment/ encystment,
cell invasion, and, in a few cases, tissue invasion (Sjid and Mckerrow, 2002). Cysteine
proteases are not only known to stimulate a Th1 immune response but also elicit
antibodies during natural infection (Wijffels et al., 1994; Rafati et al., 2001; Schnapp et
al., 2002). When the B. equi cysteine protease was inhibited with E64d in culture,
parasite propagation was inhibited (Holman et al., 2002). In order to demonstrate the
effect of a cysteine protease vaccine on a Babesia species using a mouse model, a prime-
boost vaccine strategy was designed (Sedegah et al., 2000; McConkey et al., 2003;
Rainczuk et al., 2003; Ramiro et al., 2003; Sedegah et al., 2003; Wang et al., 2004). Of
the two cysteine proteases identified in B. microti, the one with the most similarity to the
B. equi cysteine protease was selected (Holman et al., 2002; Mahmoud et al., 2002). The
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full coding sequence for the B. microti cysteine protease (CP-1) was inserted into a
plasmid expression vector. It was expected that intramuscular vaccination with the
pDNA encoding the cysteine protease would result in uptake and expression of the
encoded protein by mouse skeletal muscle cells.
The vaccine design for this study included a primary intramuscular inoculation of
pDNA encoding for B. microti cysteine protease, followed by two subcutaneous boosts
of the same or of a cysteine protease peptide (CP) adjuvanted with Alhydrogel, with
appropriate controls. Two vaccine trials were carried out with identical design except for
the challenge dose of B. microti. The results of the first vaccine trial indicated that the
challenge dose of 2 x 107 infected erythrocytes might have been too high, overwhelming
the immune response of the mice. Consequently, the mice in the second vaccine trial
were inoculated with 105 infected erythrocytes, based on the estimated number of
infected erythrocytes the tick vector would naturally inoculate into the mouse (Piesman
and Spielman, 1982; Homer et al., 2000). The hypothesis of the study stated that
vaccination of the mice with pDNA with Bmcp1 insert and the gene products would
elicit a protective immune response in BALB/c mice against B. microti challenge when
administered using a prime-boost strategy. Analysis of the daily percent parasitemia,
PCV, and seroconversion of all groups revealed that a protective immune response
against B. microti was not elicited by this vaccine strategy. The daily percent
parasitemias of the first vaccine trial showed a general trend of protection in the group
that received the pDNA/Bmcp with boosts of the pDNA/Bmcp, however there was no
statistical significance when compared to the controls. These results suggested that the
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lack of a significant difference between the groups might have been the effect of the
mice being challenged with too many parasites. However, the daily percent parasitemias
after a substantially lower challenge dose in the second vaccine trial confirmed that
neither vaccine protocol was effective. Furthermore, there were no significant
differences among the PCV values for the experimental groups versus the control groups
in either vaccine trial I or II. Finally, ELISA comparisons of the pre- and post-challenge
plasma samples from the mice in the second vaccine trial revealed that neither the
experimental nor the control mice produced cysteine protease-specific antibody.
Cumulatively, the results of the study did not support the hypothesis.
The experimental groups that received pYD52/Bmcp with two boosts of
pYD52/Bmcp may not have shown a significant immune response because the skeletal
muscle cells of the mice might not have taken up the plasmid, or, uptake of the plasmid
may not have elicited expression of the protein. On the other hand, the experimental
group that received pYD52/Bmcp with two boosts of CP/Alhydrogel may not have
stimulated a significant immune response because the CP peptide went undetected by
antigen presenting cells because it was too small. The ELISA results for this latter group,
specifically, were surprising because the CP peptide was adjuvanted with Alhydrogel,
which is known for enhancing antigenicity, in addition to activating a Th2 response and
inducing IgE and IgG (Cooper, 1994; Kenney et al., 1989). However, small peptides are
often conjugated to a larger protein in order to enhance the immune recognition of the
protein (Hanly et al., 1995). Moreover, a key reason why antibody titers may not have
been observed in the groups that received pYD52/Bmcp is that, in retrospect, the
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plasmid (pYD52) was not ideal for expression of protein in mammalian cells and is
primarily used for expression in yeast (Invitrogen, 12286-019). In the future, a different
expression vector should be used, specifically for expression of protein in a mammalian
host. Mammalian-specific plasmids have been used to express proteins in mice, resulting
in high antibody titres and protection of the host from a number of parasites, including
Plasmodium, Theileria, Leishmania, and Trypanosoma species (Sedegah et al., 1994;
Doolan et al, 1996; d’Oliviera et al., 1997; Alarcon et al, 1999).
Previously, Mahmoud et al. (2002) described the presence of cysteine proteases in
B. microti that were similar to conserved cysteine proteases found in different
geographic isolates of B. equi. Furthermore, Holman et al. (2002) showed that the
cysteine protease of B. equi is highly antigenic and is important for propagation of the
parasite. For those reasons, the cysteine protease is still a promising target for future
vaccines.
The DNA prime-boost vaccine is still a promising prospect for an effective Babesia
vaccine. A vaccine strategy utilizing a different plasmid construct for the primary
inoculation, followed by boosts of recombinant cysteine protease should be investigated
in future vaccine trials. Recombinant cysteine proteases have been shown to stimulate
the Th1 immune response, increase rate of survival, and inhibit parasite life cycles
(Wright et al., 1992; Ilg et al., 1994; Rainczuk et al., 2003; Wang et al., 2004; Fukumoto
et al., 2005) and have been shown to be effective vaccines for T. cruzi, L. major,
L. donovani, Fasciola hepatica, and Ancylostoma caninum (Wijffels et al., 1994; Engel
et al., 1998; Rafati et al., 2001; Das et al., 2001; Loukas et al., 2004). The utility of
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recombinant proteins as effective immunogens for babesiosis is demonstrated by a
recombinant surface antigen vaccine against B. gibsoni, which significantly reduced the
level of parasitemia in dogs (Fukumoto et al., 2005).
In summary, future research targeting cysteine protease vaccines against babesiosis
should consider:
1. Choice of plasmid for expression of the protein.
2. Coupling the peptide to a carrier protein.
3. Vaccinating or boosting with recombinant cysteine protease.
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